Cargando…
Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E
Hepatitis E virus (HEV) infection is an emerging disease in industrialized countries which is usually characterized by a self-limited course. However, there is an increased risk of HEV persistence in immunocompromised risk populations, comprising patients following solid organ transplantation or hem...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982013/ https://www.ncbi.nlm.nih.gov/pubmed/31947836 http://dx.doi.org/10.3390/ijerph17010341 |
_version_ | 1783491217224368128 |
---|---|
author | Schulz, Marten Biedermann, Paula Bock, Claus-Thomas Hofmann, Jörg Choi, Mira Tacke, Frank Hanitsch, Leif Gunnar Mueller, Tobias |
author_facet | Schulz, Marten Biedermann, Paula Bock, Claus-Thomas Hofmann, Jörg Choi, Mira Tacke, Frank Hanitsch, Leif Gunnar Mueller, Tobias |
author_sort | Schulz, Marten |
collection | PubMed |
description | Hepatitis E virus (HEV) infection is an emerging disease in industrialized countries which is usually characterized by a self-limited course. However, there is an increased risk of HEV persistence in immunocompromised risk populations, comprising patients following solid organ transplantation or hematological malignancies. Recently, chronic HEV infection following rituximab-containing treatment regimens has been described. Here we report five patients with chronic hepatitis E after prior rituximab therapy for various indications. We determined the immunological characteristics of these patients and analyzed the development of ribavirin (RBV) treatment failure-associated mutations in the HEV genome. One patient became chronically HEV-infected 110 months after administration of rituximab (RTX). Immunological characterization revealed that all patients exhibited significant hypogammaglobulinemia and CD4+ T cell lymphopenia. One patient permanently cleared HEV following weight-based ribavirin treatment while three patients failed to reach a sustained virological response. In depth mutational analysis confirmed the presence of specific mutations associated with RBV treatment failure in these patients. Our cases indicate that rituximab-containing treatment regimens might imply a relevant risk for persistent HEV infection even years after the last rituximab application. Moreover, we provide further evidence to prior observations suggesting that chronically HEV infected patients following RTX-containing treatment regimens might be difficult to treat. |
format | Online Article Text |
id | pubmed-6982013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69820132020-02-07 Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E Schulz, Marten Biedermann, Paula Bock, Claus-Thomas Hofmann, Jörg Choi, Mira Tacke, Frank Hanitsch, Leif Gunnar Mueller, Tobias Int J Environ Res Public Health Article Hepatitis E virus (HEV) infection is an emerging disease in industrialized countries which is usually characterized by a self-limited course. However, there is an increased risk of HEV persistence in immunocompromised risk populations, comprising patients following solid organ transplantation or hematological malignancies. Recently, chronic HEV infection following rituximab-containing treatment regimens has been described. Here we report five patients with chronic hepatitis E after prior rituximab therapy for various indications. We determined the immunological characteristics of these patients and analyzed the development of ribavirin (RBV) treatment failure-associated mutations in the HEV genome. One patient became chronically HEV-infected 110 months after administration of rituximab (RTX). Immunological characterization revealed that all patients exhibited significant hypogammaglobulinemia and CD4+ T cell lymphopenia. One patient permanently cleared HEV following weight-based ribavirin treatment while three patients failed to reach a sustained virological response. In depth mutational analysis confirmed the presence of specific mutations associated with RBV treatment failure in these patients. Our cases indicate that rituximab-containing treatment regimens might imply a relevant risk for persistent HEV infection even years after the last rituximab application. Moreover, we provide further evidence to prior observations suggesting that chronically HEV infected patients following RTX-containing treatment regimens might be difficult to treat. MDPI 2020-01-03 2020-01 /pmc/articles/PMC6982013/ /pubmed/31947836 http://dx.doi.org/10.3390/ijerph17010341 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schulz, Marten Biedermann, Paula Bock, Claus-Thomas Hofmann, Jörg Choi, Mira Tacke, Frank Hanitsch, Leif Gunnar Mueller, Tobias Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E |
title | Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E |
title_full | Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E |
title_fullStr | Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E |
title_full_unstemmed | Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E |
title_short | Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E |
title_sort | rituximab-containing treatment regimens may imply a long-term risk for difficult-to-treat chronic hepatitis e |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982013/ https://www.ncbi.nlm.nih.gov/pubmed/31947836 http://dx.doi.org/10.3390/ijerph17010341 |
work_keys_str_mv | AT schulzmarten rituximabcontainingtreatmentregimensmayimplyalongtermriskfordifficulttotreatchronichepatitise AT biedermannpaula rituximabcontainingtreatmentregimensmayimplyalongtermriskfordifficulttotreatchronichepatitise AT bockclausthomas rituximabcontainingtreatmentregimensmayimplyalongtermriskfordifficulttotreatchronichepatitise AT hofmannjorg rituximabcontainingtreatmentregimensmayimplyalongtermriskfordifficulttotreatchronichepatitise AT choimira rituximabcontainingtreatmentregimensmayimplyalongtermriskfordifficulttotreatchronichepatitise AT tackefrank rituximabcontainingtreatmentregimensmayimplyalongtermriskfordifficulttotreatchronichepatitise AT hanitschleifgunnar rituximabcontainingtreatmentregimensmayimplyalongtermriskfordifficulttotreatchronichepatitise AT muellertobias rituximabcontainingtreatmentregimensmayimplyalongtermriskfordifficulttotreatchronichepatitise |